marked.bio

multi-kinase inhibitor (RET) · small molecule

vandetanib

1 active trials, targeting RET/VEGFR/EGFR. Not approved for any biomarker on marked.bio yet.

Also known as ZD6474, Caprelsa.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
RET fusion or mutation 1 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of vandetanib.

  1. Eli Lilly 1

Trials

1 of 3 trials shown

  1. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Active, not recruiting Phase 3 Eli Lilly Started 2020Primary completion 2023-05 NCT04211337

    selpercatinib FDA EUcabozantinibvandetanib

    A defined/acceptable RET gene alteration identified in a tumor, germline deoxyribonucleic acid (DNA) or blood sample.

    RET fusion or mutationMedullary Thyroid Cancer